Westham Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Merus, Olainfarm and Aerie Pharmaceuticals.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. |  Olainfarm Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. | |
Founding Date | Founding Date 2002 | Founding Date 2003 | Founding Date 1972 | Founding Date 2005 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Utrecht, NL HQ Cambridge, US | Locations Olaine, LV HQ | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | |
Employees | Employees 1,32324% increase | Employees 172 | Employees 2,191 | Employees 3808% increase |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 3.6 b | Valuation ($) 150.2 m | Valuation ($) 722.2 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $2.2b (FY, 2024) | Revenue (est.) $43.9m (FY, 2023) | Revenue (est.) €122.2m (FY, 2020) | Revenue (est.) $194.1m (FY, 2021) |
Cost of goods | Cost of goods $306.5m (FY, 2024) | Cost of goods N/A | Cost of goods €44.5m (FY, 2020) | Cost of goods $26.8m (FY, 2021) |
Gross profit | Gross profit $1.9b (FY, 2024) | Gross profit $43.9m (FY, 2023) | Gross profit €80.1m (FY, 2020) | Gross profit N/A |
Net income | Net income ($278.2m) (FY, 2024) | Net income ($154.9m) (FY, 2023) | Net income €9.5m (FY, 2020) | Net income ($74.8m) (FY, 2021) |
Funding | ||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 149.3m | Total funding raised N/A | Total funding raised $ 388.6m |
For sources of this data, please see the company profile
View Company Profiles
Merus
HQ
Utrecht, NL
Employees
172
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View companyOlainfarm
HQ
Olaine, LV
Employees
2,191
Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia.
View companyAerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company